The University of Wisconsin-Madison has synthesized a next-generation prostate-specific member antigen (PSMA)-targeting small molecule, ART-101, for the treatment of advanced prostate cancer.
Beijing Normal University presented data on fibroblast activation protein (FAP)-targeting agents containing a nitroimidazole moiety, [68Ga]/[177Lu]AAZTA-NI-FAPI-04, being developed for the potential imaging and treatment of cancer.
Scientists from the University of Wisconsin-Madison have reported the discovery of novel carbonic anhydrase IX (CAIX) radioligands for molecular imaging in clear cell renal cell carcinoma (ccRCC).
NRG Therapeutics Ltd., has nominated NRG-5051 as its first development candidate, and secured a $5 million grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support its preclinical development of as a disease-modifying treatment for Parkinson’s disease.
Methionine adenosyltransferase 2A (MAT2A), the rate-limiting enzyme in the methionine cycle, catalyzes the formation of S-adenosylmethionine (SAM) from methionine and adenosine triphosphate (ATP).
Malaria is caused by Plasmodium species that infect hundreds of millions of people annually. Among the plasmodia, Plasmodium falciparum is considered the most dangerous due to frequent severe clinical complications and high mortality rates. Researchers from the University of California at Riverside described the discovery and mechanism of action of MED-6189, a kalihinol analog effective against drug-sensitive and drug-resistant P. falciparum strains in vitro and in vivo.
Studies evaluating the in vitro and in vivo antifungal activity, hemolytic activity and cytotoxicity of COT-832, a novel polyene macrolide antifungal that is a chemical modification of amphotericin B (AmB), were presented at IDWeek by Shionogi & Co. Ltd.
EZH2 and LSD1 are histone modification enzymes often overexpressed in several types of aggressive cancer such as colorectal, breast or prostate cancer, among others.
Aberrant expression of G9a and NSD2 has been identified in multiple types of cancer. Therefore, dual-target inhibitors blocking both pathways may be considered a potential strategy to treat solid tumors. Researchers from Sun Yat-Sen University reported on the discovery and preclinical characterization of W-4032, a dual G9a/NSD2 inhibitor aimed to be used for the treatment of solid tumors.
Centessa Pharmaceuticals plc recently detailed the discovery and preclinical characterization of a novel potent and selective orexin OX2 receptor agonist, ORX-142.
RSS
